More zaps, better rhythm? trial tests extra ablations for AFib

NCT ID NCT07021313

Ongoing Disease control Sponsor: R&D Cardiologie Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This trial compares standard versus extra pulsed field ablation applications during pulmonary vein isolation in people with atrial fibrillation. The goal is to see if more targeted ablations improve freedom from irregular heart rhythms for up to 18 months. Participants are adults with paroxysmal or persistent AFib scheduled for catheter ablation with the FARAPULSE system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pulsed field ablation (FARAPULSE system)
What this could lead to: If successful, this approach could make atrial fibrillation ablation more durable, reducing the need for repeat procedures.
What could go wrong: This is an early-stage comparison of application numbers; the extra applications may not improve outcomes and could increase risks like tamponade or stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

St. Antonius Hospital

Nieuwegein, 3435 CM, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.